| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepatitis, Autoimmune | 13 | 2021 | 254 | 4.21 | Why? |
| Cholangitis, Sclerosing | 8 | 2019 | 106 | 2.21 | Why? |
| Elasticity Imaging Techniques | 4 | 2018 | 194 | 1.37 | Why? |
| Hepatitis E | 9 | 2019 | 319 | 1.18 | Why? |
| Hepatitis E virus | 8 | 2019 | 306 | 1.01 | Why? |
| Liver | 13 | 2019 | 4007 | 0.96 | Why? |
| Liver Cirrhosis, Biliary | 2 | 2018 | 42 | 0.89 | Why? |
| Liver Cirrhosis | 10 | 2021 | 1810 | 0.81 | Why? |
| Chemical and Drug Induced Liver Injury | 3 | 2018 | 451 | 0.73 | Why? |
| Undifferentiated Connective Tissue Diseases | 1 | 2018 | 60 | 0.72 | Why? |
| Speech Disorders | 1 | 2018 | 55 | 0.70 | Why? |
| Hepatitis D | 4 | 2019 | 48 | 0.57 | Why? |
| Attention | 1 | 2018 | 335 | 0.56 | Why? |
| Hepatitis Delta Virus | 3 | 2019 | 54 | 0.53 | Why? |
| Fatty Liver | 1 | 2018 | 299 | 0.52 | Why? |
| Non-alcoholic Fatty Liver Disease | 2 | 2018 | 907 | 0.45 | Why? |
| Autoimmunity | 1 | 2019 | 841 | 0.44 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.44 | Why? |
| Diagnostic Errors | 1 | 2017 | 865 | 0.43 | Why? |
| Phytotherapy | 1 | 2017 | 743 | 0.41 | Why? |
| Immunoglobulin G | 8 | 2020 | 21571 | 0.39 | Why? |
| Biopsy | 5 | 2018 | 2811 | 0.36 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.35 | Why? |
| Cholangitis | 2 | 2019 | 81 | 0.34 | Why? |
| Liver Diseases | 3 | 2021 | 2698 | 0.34 | Why? |
| Thrombocytopenia | 1 | 2020 | 2093 | 0.32 | Why? |
| Fatigue | 1 | 2018 | 2479 | 0.32 | Why? |
| Gastroenterology | 1 | 2018 | 1352 | 0.32 | Why? |
| Antibodies, Monoclonal, Humanized | 4 | 2020 | 9335 | 0.31 | Why? |
| Patient Care Management | 1 | 2017 | 1514 | 0.31 | Why? |
| Biological Products | 1 | 2020 | 2331 | 0.30 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.30 | Why? |
| Dietary Supplements | 1 | 2017 | 2251 | 0.28 | Why? |
| Autoantibodies | 6 | 2019 | 2094 | 0.28 | Why? |
| Germany | 12 | 2021 | 9196 | 0.28 | Why? |
| Rheumatic Diseases | 1 | 2020 | 2675 | 0.28 | Why? |
| Th17 Cells | 2 | 2021 | 657 | 0.28 | Why? |
| Hepatitis Antibodies | 3 | 2018 | 100 | 0.25 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.24 | Why? |
| Immunosuppressive Agents | 6 | 2020 | 6331 | 0.23 | Why? |
| Bone Density | 3 | 2019 | 335 | 0.22 | Why? |
| Hepatitis B, Chronic | 2 | 2019 | 616 | 0.22 | Why? |
| Cholestasis | 2 | 2019 | 114 | 0.22 | Why? |
| Hepatitis B | 3 | 2018 | 888 | 0.21 | Why? |
| Interferon-alpha | 3 | 2017 | 1442 | 0.21 | Why? |
| Seroconversion | 2 | 2021 | 2515 | 0.21 | Why? |
| Brain | 1 | 2018 | 5133 | 0.21 | Why? |
| Sulfoglycosphingolipids | 1 | 2019 | 7 | 0.20 | Why? |
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2020 | 98 | 0.20 | Why? |
| Hepatitis B virus | 2 | 2017 | 882 | 0.20 | Why? |
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2019 | 237 | 0.19 | Why? |
| Bile Acids and Salts | 1 | 2019 | 91 | 0.19 | Why? |
| Gadolinium DTPA | 1 | 2018 | 45 | 0.18 | Why? |
| Viscosupplementation | 1 | 2017 | 3 | 0.18 | Why? |
| Prednisolone | 2 | 2019 | 443 | 0.18 | Why? |
| Immunoglobulin Heavy Chains | 1 | 2019 | 222 | 0.18 | Why? |
| Liver Regeneration | 1 | 2017 | 38 | 0.18 | Why? |
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 203 | 0.18 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 290 | 0.18 | Why? |
| X-Box Binding Protein 1 | 1 | 2017 | 18 | 0.18 | Why? |
| Receptors, Interleukin | 1 | 2017 | 83 | 0.18 | Why? |
| Pancreatitis, Chronic | 1 | 2017 | 37 | 0.17 | Why? |
| DNA, Circular | 1 | 2017 | 26 | 0.17 | Why? |
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2017 | 33 | 0.17 | Why? |
| Diffusion Tensor Imaging | 1 | 2018 | 125 | 0.17 | Why? |
| Humans | 66 | 2021 | 930598 | 0.17 | Why? |
| Transition to Adult Care | 1 | 2017 | 56 | 0.17 | Why? |
| T-Lymphocytes | 3 | 2019 | 6670 | 0.17 | Why? |
| Herbal Medicine | 1 | 2017 | 69 | 0.17 | Why? |
| Leptospirosis | 1 | 2018 | 103 | 0.17 | Why? |
| Amiodarone | 1 | 2018 | 110 | 0.17 | Why? |
| Prednisone | 2 | 2019 | 652 | 0.17 | Why? |
| Hepatocytes | 2 | 2017 | 549 | 0.16 | Why? |
| Thienamycins | 1 | 2017 | 72 | 0.16 | Why? |
| Mediastinitis | 1 | 2017 | 37 | 0.16 | Why? |
| Plasmodium falciparum | 1 | 2020 | 337 | 0.16 | Why? |
| Carcinoma, Hepatocellular | 2 | 2017 | 1222 | 0.16 | Why? |
| Adult | 30 | 2021 | 244371 | 0.16 | Why? |
| Guanine | 1 | 2017 | 146 | 0.16 | Why? |
| End Stage Liver Disease | 1 | 2021 | 418 | 0.16 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.16 | Why? |
| Heme Oxygenase-1 | 1 | 2017 | 90 | 0.16 | Why? |
| Middle Aged | 34 | 2021 | 270681 | 0.16 | Why? |
| Histocompatibility Antigens Class II | 1 | 2019 | 383 | 0.15 | Why? |
| Cell Transformation, Neoplastic | 1 | 2017 | 191 | 0.15 | Why? |
| Malaria, Falciparum | 1 | 2020 | 377 | 0.15 | Why? |
| Reperfusion Injury | 1 | 2017 | 178 | 0.15 | Why? |
| Female | 38 | 2021 | 380317 | 0.15 | Why? |
| Male | 37 | 2021 | 367725 | 0.15 | Why? |
| Bone and Bones | 1 | 2018 | 235 | 0.15 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2019 | 403 | 0.15 | Why? |
| Transfusion Reaction | 1 | 2018 | 245 | 0.15 | Why? |
| Acute-On-Chronic Liver Failure | 1 | 2018 | 237 | 0.15 | Why? |
| Lactic Acid | 1 | 2018 | 393 | 0.15 | Why? |
| Anti-Arrhythmia Agents | 1 | 2018 | 325 | 0.15 | Why? |
| Cell Proliferation | 3 | 2018 | 1973 | 0.15 | Why? |
| Gastroenterologists | 1 | 2019 | 259 | 0.15 | Why? |
| Antigens | 1 | 2017 | 267 | 0.14 | Why? |
| Aged | 28 | 2021 | 215776 | 0.14 | Why? |
| Antigens, CD | 1 | 2020 | 984 | 0.14 | Why? |
| Acetaminophen | 1 | 2017 | 326 | 0.14 | Why? |
| Osteoarthritis, Knee | 1 | 2017 | 158 | 0.14 | Why? |
| Tumor Suppressor Protein p53 | 1 | 2017 | 310 | 0.14 | Why? |
| Budesonide | 1 | 2017 | 192 | 0.14 | Why? |
| Peritonitis | 1 | 2017 | 217 | 0.14 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2020 | 760 | 0.14 | Why? |
| Spleen | 1 | 2019 | 877 | 0.14 | Why? |
| Neuroendocrine Tumors | 1 | 2018 | 241 | 0.14 | Why? |
| Graft Survival | 1 | 2017 | 587 | 0.14 | Why? |
| Blood Donors | 2 | 2018 | 2956 | 0.14 | Why? |
| Fibrinogen | 1 | 2020 | 1048 | 0.14 | Why? |
| Infertility, Male | 1 | 2019 | 322 | 0.14 | Why? |
| Magnetic Resonance Imaging | 4 | 2019 | 6551 | 0.13 | Why? |
| Proton Pump Inhibitors | 1 | 2019 | 377 | 0.13 | Why? |
| Pain Measurement | 1 | 2017 | 533 | 0.13 | Why? |
| Prognosis | 6 | 2020 | 32490 | 0.13 | Why? |
| Rare Diseases | 1 | 2017 | 373 | 0.13 | Why? |
| Transaminases | 3 | 2019 | 152 | 0.13 | Why? |
| Depression | 1 | 2018 | 14116 | 0.13 | Why? |
| Antibodies, Viral | 3 | 2020 | 51949 | 0.13 | Why? |
| Toll-Like Receptor 7 | 1 | 2017 | 402 | 0.13 | Why? |
| Aspartate Aminotransferases | 1 | 2020 | 1394 | 0.13 | Why? |
| Osteoporosis | 1 | 2019 | 410 | 0.13 | Why? |
| Stress, Physiological | 1 | 2017 | 378 | 0.12 | Why? |
| Liver Transplantation | 5 | 2021 | 2864 | 0.12 | Why? |
| Cohort Studies | 7 | 2021 | 36005 | 0.12 | Why? |
| Hematologic Diseases | 1 | 2019 | 614 | 0.12 | Why? |
| Neuropsychological Tests | 1 | 2018 | 954 | 0.12 | Why? |
| Influenza, Human | 1 | 2017 | 10779 | 0.12 | Why? |
| Ischemia | 2 | 2017 | 901 | 0.12 | Why? |
| Propensity Score | 1 | 2021 | 2690 | 0.12 | Why? |
| Disease Progression | 4 | 2019 | 13580 | 0.12 | Why? |
| Adipose Tissue | 1 | 2017 | 612 | 0.11 | Why? |
| Seroepidemiologic Studies | 4 | 2020 | 10017 | 0.11 | Why? |
| Disease Notification | 1 | 2018 | 639 | 0.11 | Why? |
| Predictive Value of Tests | 5 | 2018 | 9537 | 0.11 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2017 | 398 | 0.11 | Why? |
| Contrast Media | 1 | 2018 | 1011 | 0.11 | Why? |
| Denmark | 1 | 2019 | 2654 | 0.11 | Why? |
| Hepatitis C | 3 | 2018 | 1514 | 0.11 | Why? |
| Mice | 10 | 2019 | 21357 | 0.11 | Why? |
| Case-Control Studies | 6 | 2020 | 17671 | 0.11 | Why? |
| Retrospective Studies | 15 | 2020 | 105322 | 0.11 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.11 | Why? |
| Biomarkers | 5 | 2020 | 23361 | 0.11 | Why? |
| Autoimmune Diseases | 3 | 2019 | 1996 | 0.10 | Why? |
| Drug Prescriptions | 1 | 2019 | 1062 | 0.10 | Why? |
| Pancreatic Neoplasms | 1 | 2018 | 609 | 0.10 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.10 | Why? |
| Hepacivirus | 2 | 2017 | 1509 | 0.10 | Why? |
| Communicable Diseases, Imported | 1 | 2018 | 843 | 0.10 | Why? |
| Immunocompromised Host | 4 | 2020 | 5150 | 0.10 | Why? |
| Survival Analysis | 2 | 2020 | 7592 | 0.10 | Why? |
| Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.10 | Why? |
| Intensive Care Units | 4 | 2021 | 29594 | 0.10 | Why? |
| Mass Screening | 3 | 2018 | 8005 | 0.10 | Why? |
| Interferon-gamma | 1 | 2019 | 2711 | 0.09 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2019 | 2483 | 0.09 | Why? |
| Immunologic Memory | 1 | 2021 | 3362 | 0.09 | Why? |
| Mice, Knockout | 3 | 2019 | 1815 | 0.09 | Why? |
| Serologic Tests | 2 | 2020 | 4359 | 0.09 | Why? |
| Absorptiometry, Photon | 2 | 2019 | 168 | 0.09 | Why? |
| Young Adult | 14 | 2021 | 93724 | 0.09 | Why? |
| Animals | 13 | 2019 | 78931 | 0.09 | Why? |
| Ribavirin | 3 | 2019 | 1182 | 0.09 | Why? |
| Cell Division | 2 | 2017 | 136 | 0.09 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.09 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2019 | 2262 | 0.08 | Why? |
| Microbiota | 1 | 2018 | 1240 | 0.08 | Why? |
| Disease Models, Animal | 4 | 2018 | 10998 | 0.08 | Why? |
| Heterografts | 2 | 2018 | 203 | 0.08 | Why? |
| Coinfection | 2 | 2017 | 6820 | 0.08 | Why? |
| Azathioprine | 2 | 2019 | 161 | 0.08 | Why? |
| C-Reactive Protein | 2 | 2020 | 7972 | 0.08 | Why? |
| Anti-Bacterial Agents | 2 | 2020 | 10083 | 0.08 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.08 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.08 | Why? |
| Genotype | 4 | 2019 | 4697 | 0.08 | Why? |
| Diagnosis, Differential | 2 | 2018 | 7220 | 0.08 | Why? |
| Molecular Mimicry | 2 | 2018 | 190 | 0.08 | Why? |
| Hematologic Neoplasms | 1 | 2019 | 2105 | 0.07 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Macrophages | 1 | 2017 | 2784 | 0.07 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.07 | Why? |
| Glucocorticoids | 2 | 2019 | 4431 | 0.07 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.07 | Why? |
| Periodicals as Topic | 1 | 2018 | 1492 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.07 | Why? |
| B-Lymphocytes | 1 | 2019 | 4418 | 0.07 | Why? |
| Patient Satisfaction | 1 | 2017 | 2517 | 0.07 | Why? |
| Remission Induction | 2 | 2019 | 950 | 0.07 | Why? |
| Treatment Outcome | 6 | 2020 | 51732 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.07 | Why? |
| Hepatectomy | 2 | 2017 | 276 | 0.07 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2020 | 5837 | 0.07 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.07 | Why? |
| Immunoglobulin M | 2 | 2018 | 9091 | 0.06 | Why? |
| Immunotherapy | 1 | 2017 | 2421 | 0.06 | Why? |
| False Positive Reactions | 2 | 2020 | 1338 | 0.06 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.06 | Why? |
| Adolescent | 9 | 2021 | 86841 | 0.06 | Why? |
| Inflammation | 4 | 2021 | 13255 | 0.06 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.06 | Why? |
| Sensitivity and Specificity | 3 | 2020 | 22971 | 0.06 | Why? |
| Cells, Cultured | 3 | 2020 | 5835 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.06 | Why? |
| Travel | 2 | 2018 | 7220 | 0.06 | Why? |
| Cytokines | 3 | 2019 | 15010 | 0.06 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.05 | Why? |
| Cell Differentiation | 2 | 2018 | 1338 | 0.05 | Why? |
| Fever | 1 | 2018 | 7795 | 0.05 | Why? |
| Clone Cells | 1 | 2021 | 312 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.05 | Why? |
| Laparoscopy | 1 | 2012 | 1532 | 0.05 | Why? |
| Immunogenetic Phenomena | 1 | 2019 | 61 | 0.05 | Why? |
| Antigens, CD1d | 1 | 2019 | 12 | 0.05 | Why? |
| RNA, Viral | 5 | 2019 | 32276 | 0.05 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.05 | Why? |
| Serpins | 1 | 2019 | 67 | 0.05 | Why? |
| Biosynthetic Pathways | 1 | 2019 | 97 | 0.05 | Why? |
| Hepatitis, Chronic | 1 | 2019 | 53 | 0.05 | Why? |
| Sphincterotomy | 1 | 2018 | 4 | 0.05 | Why? |
| Receptors, Chemokine | 1 | 2019 | 56 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2018 | 7218 | 0.05 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.05 | Why? |
| Bone Resorption | 1 | 2019 | 61 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Viscosupplements | 1 | 2017 | 17 | 0.04 | Why? |
| Constriction | 1 | 2017 | 44 | 0.04 | Why? |
| Transplantation Chimera | 1 | 2017 | 17 | 0.04 | Why? |
| Constriction, Pathologic | 1 | 2019 | 212 | 0.04 | Why? |
| Oncogene Protein v-akt | 1 | 2017 | 10 | 0.04 | Why? |
| Induction Chemotherapy | 1 | 2019 | 149 | 0.04 | Why? |
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 29 | 0.04 | Why? |
| Elasticity | 1 | 2017 | 70 | 0.04 | Why? |
| Hepatic Stellate Cells | 1 | 2017 | 35 | 0.04 | Why? |
| Biliverdine | 1 | 2017 | 50 | 0.04 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.04 | Why? |
| Chimera | 1 | 2017 | 83 | 0.04 | Why? |
| Alkaline Phosphatase | 1 | 2018 | 257 | 0.04 | Why? |
| Injections, Intra-Articular | 1 | 2017 | 104 | 0.04 | Why? |
| Natural Killer T-Cells | 1 | 2019 | 191 | 0.04 | Why? |
| Cyclic AMP | 1 | 2017 | 76 | 0.04 | Why? |
| Tropical Climate | 1 | 2018 | 179 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2020 | 536 | 0.04 | Why? |
| Mice, Inbred C57BL | 2 | 2019 | 5542 | 0.04 | Why? |
| Actins | 1 | 2017 | 108 | 0.04 | Why? |
| Hepatitis B Core Antigens | 1 | 2017 | 76 | 0.04 | Why? |
| Keratin-18 | 1 | 2017 | 114 | 0.04 | Why? |
| Asia, Southeastern | 1 | 2018 | 390 | 0.04 | Why? |
| Organ Size | 1 | 2018 | 384 | 0.04 | Why? |
| Virus Integration | 1 | 2017 | 96 | 0.04 | Why? |
| Mutagenesis | 1 | 2019 | 394 | 0.04 | Why? |
| Surveys and Questionnaires | 3 | 2021 | 43792 | 0.04 | Why? |
| Pneumonia | 1 | 2017 | 5652 | 0.04 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.04 | Why? |
| STAT Transcription Factors | 1 | 2017 | 173 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Gene Expression | 2 | 2017 | 3332 | 0.04 | Why? |
| Transcriptional Activation | 1 | 2017 | 196 | 0.04 | Why? |
| Models, Animal | 1 | 2019 | 788 | 0.04 | Why? |
| Child | 4 | 2021 | 70012 | 0.04 | Why? |
| Hepatitis A | 1 | 2018 | 140 | 0.04 | Why? |
| Lamivudine | 1 | 2017 | 210 | 0.04 | Why? |
| Myeloid Cells | 1 | 2021 | 808 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2017 | 501 | 0.04 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2020 | 724 | 0.04 | Why? |
| Drainage | 1 | 2019 | 414 | 0.04 | Why? |
| Risk Factors | 7 | 2018 | 71621 | 0.04 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2017 | 309 | 0.04 | Why? |
| Bilirubin | 1 | 2018 | 503 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Genotyping Techniques | 1 | 2018 | 360 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Proline | 1 | 2017 | 345 | 0.04 | Why? |
| Fluorescent Antibody Technique | 1 | 2017 | 835 | 0.04 | Why? |
| Cell Death | 1 | 2017 | 536 | 0.04 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.03 | Why? |
| Proportional Hazards Models | 2 | 2017 | 6543 | 0.03 | Why? |
| Lipopeptides | 1 | 2017 | 229 | 0.03 | Why? |
| Regeneration | 1 | 2017 | 429 | 0.03 | Why? |
| Liver Failure, Acute | 1 | 2017 | 279 | 0.03 | Why? |
| Interleukin-17 | 1 | 2019 | 602 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Cell Movement | 1 | 2017 | 695 | 0.03 | Why? |
| France | 2 | 2020 | 12074 | 0.03 | Why? |
| Pneumonia, Bacterial | 1 | 2021 | 843 | 0.03 | Why? |
| Chemokine CXCL10 | 1 | 2017 | 565 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Polymerase Chain Reaction | 2 | 2018 | 6740 | 0.03 | Why? |
| Imaging, Three-Dimensional | 1 | 2018 | 680 | 0.03 | Why? |
| Odds Ratio | 2 | 2017 | 5861 | 0.03 | Why? |
| Prevalence | 3 | 2021 | 25773 | 0.03 | Why? |
| Lipopolysaccharides | 1 | 2017 | 848 | 0.03 | Why? |
| Latin America | 1 | 2018 | 1721 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2019 | 2739 | 0.03 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.03 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2019 | 830 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 2309 | 0.03 | Why? |
| Cell Line | 2 | 2017 | 12040 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Rituximab | 1 | 2019 | 1096 | 0.03 | Why? |
| Stents | 1 | 2018 | 916 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2018 | 11304 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Needs Assessment | 1 | 2021 | 2352 | 0.03 | Why? |
| Liver Function Tests | 1 | 2017 | 1325 | 0.03 | Why? |
| Signal Transduction | 2 | 2017 | 7207 | 0.03 | Why? |
| Postoperative Hemorrhage | 1 | 2012 | 183 | 0.03 | Why? |
| International Normalized Ratio | 1 | 2012 | 300 | 0.03 | Why? |
| Whole Genome Sequencing | 1 | 2021 | 3239 | 0.03 | Why? |
| NF-kappa B | 1 | 2017 | 1301 | 0.02 | Why? |
| Intestinal Perforation | 1 | 2012 | 178 | 0.02 | Why? |
| Polymorphism, Genetic | 1 | 2017 | 1074 | 0.02 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2019 | 3776 | 0.02 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Academic Medical Centers | 1 | 2021 | 3088 | 0.02 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.02 | Why? |
| Disease Outbreaks | 1 | 2017 | 27595 | 0.02 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.02 | Why? |
| Phenotype | 1 | 2019 | 4037 | 0.02 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 11367 | 0.02 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3633 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Viral Load | 2 | 2017 | 15850 | 0.02 | Why? |
| Universities | 1 | 2021 | 4374 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Body Mass Index | 1 | 2019 | 4306 | 0.02 | Why? |
| Platelet Count | 1 | 2012 | 1381 | 0.02 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.02 | Why? |
| Critical Illness | 2 | 2020 | 17281 | 0.02 | Why? |
| Virus Replication | 2 | 2017 | 14331 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 2426 | 0.02 | Why? |
| Monocytes | 1 | 2017 | 2978 | 0.02 | Why? |
| Diabetes Complications | 1 | 2017 | 2358 | 0.02 | Why? |
| Chronic Disease | 1 | 2019 | 5139 | 0.02 | Why? |
| Survival Rate | 1 | 2019 | 9206 | 0.02 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2017 | 4002 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Ultrasonography | 1 | 2019 | 4409 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2021 | 7330 | 0.01 | Why? |
| Antiviral Agents | 3 | 2019 | 41703 | 0.01 | Why? |
| Registries | 1 | 2021 | 12327 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Child, Preschool | 2 | 2017 | 36283 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.01 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.01 | Why? |
| Hospitals, University | 1 | 2012 | 4173 | 0.01 | Why? |
| India | 1 | 2017 | 11875 | 0.01 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Pregnancy Complications, Infectious | 1 | 2019 | 11559 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Infant | 1 | 2012 | 30274 | 0.01 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |
| Risk Assessment | 1 | 2012 | 25439 | 0.01 | Why? |
| Prospective Studies | 1 | 2012 | 43301 | 0.01 | Why? |